Drugs to Watch: The Expanding Role of Bispecific Antibodies in Personalized Medicine

For many autoimmune diseases and rare blood disorders, today’s treatments only go so far, and often come with the tradeoff of broad immunosuppression. But what if we could reprogram the immune system with better precision? That’s exactly what bispecific and multispecific antibodies are starting to make possible.

Beyond CD3: A Broader Therapeutic Horizon

Bispecific antibodies (bsAbs) bind two different antigens at once, letting them bring immune cells into direct contact with diseased targets or block multiple disease pathways at the same time.

In oncology, bispecific T-cell engagers are picking up serious steam. With FDA approvals on the rise and easier, off-the-shelf manufacturing, they’re quickly becoming a new mainstay of cancer immunotherapy. And now, bsAbs are moving beyond CD3 T-cell recruitment into broader mechanisms and more diverse disease targets.

One standout is NXT007, a next-generation bsAb from Roche that mimics Factor VIII by bridging activated Factors IX and X. In early-phase studies it delivered very low bleed rates without relying on immune-cell engagement. It’s part of a broader wave of bsAbs moving beyond cancer into autoimmune and neurodegenerative diseases, where dialing in the immune response with precision really matters. 

Also moving the needle is trontinemab, built using Roche’s Brainshuttle™ platform. This year, the company reported full amyloid clearance in 91% of Alzheimer’s patients, along with a strong safety profile—an encouraging sign of what BBB-penetrant bsAbs might make possible in brain diseases.

The Market Signals Are Clear

Scientific progress is only half the story. The global bsAb market is projected to reach roughly $484 billion USD by 2034, fueled in-part by their expanding role in chronic and rare diseases. At the same time, the broader personalized medicine market is expected to more than double.

Big pharma is on board. In 2024 alone, companies like Merck, Novartis, and J&J struck multi-billion-dollar deals to license or acquire bsAb platforms — many aimed squarely at autoimmune and inflammatory conditions.

Engineering Precision, Managing Complexity 

Of course, with this kind of potential comes complexity. Unlike standard monoclonal antibodies, bsAbs must be carefully engineered to avoid mispairing, aggregation, or off-target effects. Even with optimized scaffolds, they’re more complicated—and costlier—to make, averaging 40% more per molecule than traditional mAbs.

One of the trickiest challenges? Understanding how they actually work. BsAbs aren’t just two antibodies fused together; their dual-targeting nature often leads to nonlinear effects that can’t be predicted by studying the parts alone. That’s why developers need tools that go beyond binding to see how these molecules behave in real biological systems.

Tools That Meet the Moment 

As the field grows, so does the need for technologies that measure both binding and function. Sartorius is helping researchers meet that challenge with tools that provide real-time insights across the development pipeline.

• Octet^® Biolayer Interferometry (BLI) delivers fast, fluidics-free binding kinetics to evaluate both arms of a bsAb—helping scientists screen and fine-tune candidates early
• The iQue^® High-Throughput Screening Cytometry Platform makes it fast and easy to assess functional responses in vitro, from T-cell activation to cytokine modulation
• The Incucyte^® Live-Cell Imaging System captures dynamic changes over time, providing a window into subtle or delayed effects that might otherwise go unseen

Together, these platforms help researchers rank candidates not just by what they bind, but by what they do, a critical distinction in the era of personalized medicine. Check out this application note for a great example of how high-throughput live-cell analysis and screening by cytometry work together to provide insights into the CD3xCD19 bispecific T-cell Engager (BiTE) antibody's role in targeted tumor cell destruction.

Navigating Safety and Immunogenicity 

Safety remains a top concern, especially for immune-engaging therapies. Risks like cytokine release syndrome (CRS), neurotoxicity (ICANS), and unintended immune activation are real, particularly in patients with autoimmune or rare diseases.

To manage those risks, developers are using strategies like step-up dosing, CD3 affinity tuning, and valency optimization. But these methods rely heavily on predictive analytics and real-time monitoring, reinforcing the need for early functional insights.

As bsAbs evolve into even more complex forms (think trispecifics or bsAb-drug conjugates), tools like AI-assisted design and in silico immunogenicity screening will likely become part of the standard toolkit.

The Takeaway

Bispecific and multispecific antibodies are already reshaping what’s possible in precision medicine. As they move into new indications, from cancer to chronic disease, they’re bringing with them new opportunities, new questions, and the need for smarter, faster development tools.

At Sartorius, we’re proud to support that progress by helping scientists turn breakthrough ideas into real-world impact.